Protara Therapeutics, Inc.

Protara Therapeutics, Inc. is a New York-based clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its pipeline centers on TARA-002, an investigational cell therapy, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, with development activities primarily in the United States.

14.58

14.58

— Protara Therapeutics, Inc.
%
TARA-002 oncology program50% Investigational cell therapy being developed for non-muscle invasive bladder cancer and other oncology uses.
TARA-002 rare disease program30% Development of TARA-002 for lymphatic malformations and related rare disease indications.
IV Choline Chloride20% Investigational intravenous choline replacement therapy for patients receiving parenteral support.

Protara does not yet sell approved products, so its direct customers are future patients, physicians, and treatment...

  • NMIBC patients and urologistsprimary

    Patients with non-muscle invasive bladder cancer and the urologists who would prescribe intravesical therapy if TARA-002 is approved.

  • Rare disease patients and pediatric specialistsprimary

    Patients with lymphatic malformations and related maxillofacial cysts treated by pediatric surgeons and specialty clinicians.

  • Parenteral support patients and hospital clinicianssecondary

    Patients receiving nutrition and fluids through parenteral support who could use IV Choline Chloride if approved.

  • Clinical trial investigatorsprimary

    Hospitals and research centers that enroll patients, administer study drug, and generate clinical data for the pipeline.

Protara is headquartered in New York, and its development programs are managed from the United States...

  • •Headquartered in New York City
  • •Clinical development managed from the United States
  • •Worldwide rights to TARA-002 exclude Japan and Taiwan
  • •Future commercialization could extend beyond the U.S.
  • •Current operations are primarily U.S.-based

Protara’s strategy is to advance TARA-002 through clinical development in NMIBC and lymphatic malformations while...

01
Advance TARA-002 clinical programsshort-term

Clinical proof-of-concept is the main value driver for a company with no approved products.

02
Build regulatory and commercial optionalitymedium-term

Successful approvals would create the basis for future partnering or commercialization.

03
Protect pipeline economics through IPlong-term

Patent protection supports exclusivity in competitive oncology and rare disease markets.

Protara is exposed to the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval...

critical

Clinical development failure

The company’s value depends on positive data from TARA-002 and IV Choline Chloride trials.

Scope
TARA-002 and IV Choline Chloride programs
Materiality
high
high

Regulatory approval risk

Neither product candidate has FDA or other regulatory approval, so commercialization is not assured.

Scope
All pipeline assets
Materiality
high
high

Financing risk

The company has no current revenue and must fund ongoing R&D and trials externally.

Scope
Corporate liquidity and development spend
Materiality
high
high

Third-party manufacturing and supply risk

Clinical and future commercial supply depend on outside contractors and sole-source vendors.

Scope
Drug substance, fill-finish, and distribution
Materiality
medium
medium

Competitive risk

Established therapies and better-capitalized developers compete in NMIBC and rare disease markets.

Scope
NMIBC and oncology pipeline
Materiality
medium
Research and development prepaid and accrued expenses
Can shift quarterly R&D expense and operating loss
Stock-based compensation
Affects operating expenses and reported losses
Investment income on cash and marketable securities
Can partially offset operating losses

Protagenic Therapeutics, Inc.\new

PTIX · Pharmaceutical Preparations

LISATA THERAPEUTICS, INC.

LSTA · Pharmaceutical Preparations

Nkarta, Inc.

NKTX · Pharmaceutical Preparations

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Tyra Biosciences, Inc.

TYRA · Pharmaceutical Preparations

Galera Therapeutics, Inc.

GRTX · Pharmaceutical Preparations

: 29/04/2026